Strong Revenue Growth:
Revenue and Galleri test volumes increased through 2025, with multiple quarters of year‑over‑year gains and more than 185,000 tests performed, indicating rising adoption.
Strategic Partnerships:
Collaborations with NHS England, Samsung for Asia expansion, and integrations with Quest, athenahealth, and digital‑health channels broaden distribution and access.
Investor Backing & Capital Strength:
Following the 2024 spin‑off, the company raised additional capital, ended 2025 with a substantial cash balance, and guided to a multiyear runway to fund commercialization and evidence generation.
